July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Evaluation of birth weight and gestational age in infants with treatment requiring retinopathy of prematurity in ROPE-SOS trial
Author Affiliations & Notes
  • Nita Valikodath
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, United States
  • Parag Shah
    Aravind Eye Hospital, Coimbatore, India
  • Robison Vernon Paul Chan
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, United States
  • J. Peter Campbell
    Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, United States
  • Michael F Chiang
    Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, United States
  • Kelley Bohm
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, United States
  • Ru-ik Chee
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, United States
  • Shelbi Olson
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, United States
  • Flavius Beca
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, United States
  • Ramachandran Ramyadevi
    Aravind Eye Hospital, Coimbatore, India
  • Subramani Murugan
    Aravind Eye Hospital, Coimbatore, India
  • Narendran Venkatapathy
    Aravind Eye Hospital, Coimbatore, India
  • Footnotes
    Commercial Relationships   Nita Valikodath, None; Parag Shah, None; Robison Chan, Alcon (C), Allergan (C), Bausch and Lomb (C), Visunex (S); J. Peter Campbell, Allergan (C); Michael Chiang, National Institutes of Health, Bethesda, Maryland; R01 EY019474 (F), National Institutes of Health; P30EY010572 (F), Novartis (C), NSF SCH-1622679 (F); Kelley Bohm, None; Ru-ik Chee, None; Shelbi Olson, None; Flavius Beca, None; Ramachandran Ramyadevi, None; Subramani Murugan, None; Narendran Venkatapathy, None
  • Footnotes
    Support  United States Agency for International Development (USAID), PGRD-14-0001-14; P30 EY001792, Core Grant for Vision Research from the National Institutes of Health, Bethesda, Maryland; RPB departmental grant (Unrestricted Grant from Research to Prevent Blindness)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2749. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nita Valikodath, Parag Shah, Robison Vernon Paul Chan, J. Peter Campbell, Michael F Chiang, Kelley Bohm, Ru-ik Chee, Shelbi Olson, Flavius Beca, Ramachandran Ramyadevi, Subramani Murugan, Narendran Venkatapathy; Evaluation of birth weight and gestational age in infants with treatment requiring retinopathy of prematurity in ROPE-SOS trial. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2749.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To characterize the patients in the Retinopathy of Prematurity Eradication – Save Our Sight (ROPE-SOS) trial that required treatment and to determine any differences in birth weight (BW) and gestational age (GA) among those with ROP requiring laser vs anti-vascular endothelial growth factor (anti-VEGF) injections.

Methods : A mobile ROP tele-screening team called ROPE-SOS [Retinopathy of Prematurity Eradication – Save Our Sight] performed screening examinations in South India between August 12, 2015 and September 30, 2015. Digital retinal images of the preterm infants were captured using the Retcam Shuttle (Clarity Medical Systems, Pleasonton, CA). These images were transmitted to Aravind Eye hospital in Coimbatore and a remote ROP expert determined acuity of disease and recommended follow up and treatment. Data regarding infant demographics, retinal exam, diagnosis, and treatment were recorded. Difference in BW or GA were determined between infants who were treated with laser vs infants who were treated with anti-VEGF injections. Asymmetric disease was defined as infant with eyes with different categories of ROP in the right eye vs the left eye. Statistical analysis was performed using STATA.

Results : A total of 3620 patients were screened. Average BW of those screened was 1746.83 ± 453.15 grams (g) and GA was 33.73 ± 2.84 weeks. A total of 103 (2.46%) patients were treated. Average BW of those treated was 1303.88 ± 359.94 g and GA was 30.22 ± 2.81 weeks. Of those patients that received treatment, 13.59% had to receive multiple treatments. Of all infants treated, 71.85% received laser, 42.72% received anti-VEGF injections (40.78% bevacizumab, 1.94% ranibizumab), and 0.97% had surgery. Of those treated, 25.40% had asymmetric disease. BW was 1287.54 ± 342.89g in the laser treatment group and 1351.029 ± 55.08 g in the anti-VEGF group (95% confidence interval (CI) -208.67-81.70, p=0.39). GA was 30.33 ± 2.65 weeks in the laser treatment group and 30.15 ± 3.06 weeks in the anti-VEGF injection group (95% CI -1.04-1.40, p=0.77).

Conclusions : The ROPE-SOS program was able to successfully screen and treat infants at risk for ROP through a telemedicine based screening program in rural India. There was no statistically significant difference in birth weight or gestational age in infants that received laser treatment vs anti-VEGF injections. Only 1 patient required vitrectomy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×